Physician profile
Deborah A Hahn
NPI 1629075932
$6,314.88
in general payments reported to CMS, 2019-2025
43 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $695 · 2021: $769 · 2022: $269 · 2023: $769 · 2024: $2,057 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,536 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,535.99 |
| Education | $350.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,222.48 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,123.96 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $933.53 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $329.90 | 2020-2025 | Proclaim, Octrode, Eterna |
| Lilly USA, LLC | $318.72 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.34 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Edwards Lifesciences Corporation | $254.60 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Pfizer INC. | $198.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $167.32 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $148.41 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $142.14 | 2024 | Voquezna |
| Amgen INC. | $115.88 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $96.33 | 2019-2020 | |
| Astellas Pharma US INC | $91.74 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $73.14 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.